BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-10 out of 99 found
  Current Search:      

HTML
100%
The Pharmafocus Interview: Elmar Schnee
Merck's head of pharmaceuticals on the advantages of a diverse business model and the maddening 'disaster' that is Germany's cost effectiveness body IQWIG Germany's Merck has the kind of business model that investors warm to during times of...
Pharmafocus:  Jan 6 2009 10:29AM Find similar documents
HTML
100%
The Pharmafocus Interview: Elmar Schnee
Merck's head of pharmaceuticals on the advantages of a diverse business model and the maddening 'disaster' that is Germany's cost effectiveness body IQWIG Germany's Merck has the kind of business model that investors warm to during times of...
Pharmafocus:  Jan 6 2009 10:29AM Find similar documents
HTML
100%
NICE makes end-of-life drugs more available
High-cost drugs that extend the lives of terminally ill patients will be more readily approved for NHS use, thanks to a change of approach from NICE.

The body has altered its appraisal process to make more end-of life drugs available by...

Pharmafocus:  Jan 6 2009 10:26AM Find similar documents
HTML
100%
NICE makes end-of-life drugs more available
High-cost drugs that extend the lives of terminally ill patients will be more readily approved for NHS use, thanks to a change of approach from NICE.

The body has altered its appraisal process to make more end-of life drugs available by...

Pharmafocus:  Jan 6 2009 9:02AM Find similar documents
HTML
100%
Most acute NHS trusts independent from government
More than half of all acute NHS trusts have now been awarded foundation status, making them free to operate outside government control.

This month Central Manchester University Hospitals will become the 113th foundation trust - for the...

Pharmafocus:  Jan 5 2009 7:31AM Find similar documents
HTML
100%
GSK halts political funding
GlaxoSmithKline will no longer make corporate political donations in a bid to make its dealings with governments more transparent and avoid accusations of lobbying.

GSK, like a number of other pharma firms, has made political contributions...

Pharmafocus:  Jan 5 2009 7:31AM Find similar documents
HTML
100%
GSK halts political funding
GlaxoSmithKline will no longer make corporate political donations in a bid to make its dealings with governments more transparent and avoid accusations of lobbying.

GSK, like a number of other pharma firms, has made political contributions...

Pharmafocus:  Jan 5 2009 6:43AM Find similar documents
HTML
100%
Most acute NHS trusts independent from government
More than half of all acute NHS trusts have now been awarded foundation status, making them free to operate outside government control.

This month Central Manchester University Hospitals will become the 113th foundation trust - for the...

Pharmafocus:  Jan 5 2009 6:43AM Find similar documents
HTML
100%
Reforms launched with call for action on European competitiveness
The European Commission has launched what it calls a 'renewed vision' for the European pharmaceutical industry, which includes plans to provide more information to patients and a plea to increase competitiveness.

The Commission's vice...

Pharmafocus:  Jan 2 2009 10:55PM Find similar documents
HTML
100%
Abraxis Biosciences launches Abraxane in Europe
US biotech company Abraxis BioScience has launched its innovative breast cancer treatment Abraxane in Europe.

The drug is a variant on the commonly used treatment paclitaxel, but the science behind Abraxane makes it different from its...

Pharmafocus:  Jan 2 2009 10:55PM Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.